• Purchase order from National Institutes of Health in Mid-Atlantic region
• First installations in Pacific Northwest with St. Charles Health System
• Two-site commercial agreement with UF Health in Central Florida
• Contract with Texas Health Presbyterian Hospital Dallas in North Texas

Cyclopharm Ltd has provided an update on the continued execution of its US commercial strategy for Technegas, with recent developments spanning four key regions. In the Mid-Atlantic region, the company received a purchase order from the National Institutes of Health, establishing Technegas within a leading US government research and clinical institution. In the Pacific Northwest, Cyclopharm installed Technegas at two sites within the St. Charles Health System, marking the company's first clinical presence in this region. In Central Florida, Cyclopharm executed a two-site agreement with UF Health, building on its existing presence in other major independent delivery networks (IDNs) in the area. In North Texas, the company secured a contract with Texas Health Presbyterian Hospital Dallas, part of one of the largest non-profit health systems in the US. These developments demonstrate Cyclopharm's continued scaling of its US commercial platform for Technegas across government institutions, regional health systems, and major metropolitan IDNs.

Cyclopharm remains confident in achieving 250-300 Technegas installations in the US by the second half of 2026.